IR@PKUHSC  > 北京大学医药卫生分析中心
学科主题公共卫生
Tc-99m-3PRGD(2) SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab
Ma, Qingjie1; Min, Kaiyin1; Wang, Ting1; Chen, Bin1; Wen, Qiang1; Wang, Fan2; Ji, Tiefeng1; Gao, Shi1
关键词Tc-99m-3PRGD(2) SPECT/CT Lung cancer Response Prediction Bevacizumab
刊名ANNALS OF NUCLEAR MEDICINE
2015-07-01
DOI10.1007/s12149-015-0975-5
29期:6页:519-527
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]POSITRON-EMISSION-TOMOGRAPHY ; DRUG-RESISTANCE ; BREAST-CANCER ; SOLID TUMOR ; INTEGRIN ; ADENOCARCINOMA ; EXPRESSION ; CISPLATIN ; SURVIVAL ; THERAPY
英文摘要

Functional imaging can help clinicians assess the individual response of advanced nonsquamous non-small cell lung cancer (NSCLC) to chemoradiation therapy plus bevacizumab. Our purpose is to investigate the ability of Tc-99m-3PRGD(2) single photon emission computed tomography/computed tomography (SPECT/CT) in predicting the early response to treatment.

Patients with advanced nonsquamous NSCLC diagnosed by histological or cytological examination were imaged with Tc-99m-3PRGD(2) SPECT/CT at 3 time points: 1-3 days before the start of treatment (SPECT1), 40 Gy radiotherapy with 2 cycles of chemotherapy plus bevacizumab (SPECT2) and 4 weeks after chemoradiotherapy plus bevacizumab (SPECT3). The images were evaluated semiquantitatively by measuring the tumor to non-tumor ratio (T/N) and calculating the percentage change in T/N ratio. Short-term outcome was assessed by the treatment response evaluation according to the Response Evaluation Criteria in Solid Tumors criteria as: complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Patients were divided two groups: responders (CR and PR) and nonresponders (SD and PD). To determine a threshold for percent reduction in T/N ratios, receiver-operating characteristic (ROC) curve analysis was used. Patients were grouped again based on the threshold of P1 (the change percentage from SPECT1 to SPECT2) and P2 (the change percentage from SPECT1 to SPECT3): P1 responders and P1 nonresponders; P2 responders and P2 nonresponders. Patients were followed up starting 4 weeks after completion of therapy and then every 3 months for the first 2 years and every 6 months after 2 years. OS of P1 responders, P1 nonresponders, P2 responders and P2 nonresponders was estimated and graphically illustrated using the Kaplan-Meier method and the log-rank test was used to test the null hypotheses of equal OS in subgroups of patients.

A total of 28 patients completed all imaging and treatment. All primary lung tumors were well visualized on SPECT1. The mean T/N ratio of SPECT1 in responders and nonresponders was not statistically different (2.73 +/- A 0.59 vs. 2.59 +/- A 0.52, p > 0.05). At SPECT2 and SPECT3, the mean T/N ratios were both lower in the responders compared with the nonresponders and had statistical significance (p < 0.05). P1 and P2 in the responders was larger than the nonresponders with significant difference (P1: 34.18 +/- A 21.55 % vs. 9.02 +/- A 14.02 %, p < 0.05; P2: 53.02 +/- A 15.50 % vs. 7.74 +/- A 37.95 %, p < 0.05). The optimal threshold of P1 that can discriminate between P1 responders and P1 nonresponders was greater than 25.9 % reduction, and that of P2 that can discriminate between P2 responders and P2 nonresponders was 34.0 % reduction. The area under the ROC curve (AUC) of P1 and P2 for determining residual disease was 0.856 and 0.909, respectively; but there was no statistical significance between them (p > 0.05). There was a significant difference for OS between P1 responders and P1 nonresponders (p < 0.05), and also for OS between P2 responders and P2 nonresponders (p < 0.05). But there was no difference between the P1 responders and P2 responders (p > 0.05), or between the P1 nonresponders and P2 nonresponders (p > 0.05).

A Tc-99m-3PRGD(2) SPECT/CT after two cycles of chemoradiotherapy plus bevacizumab can predict patients who will have a better response to treatment and survival.

语种英语
WOS记录号WOS:000358175300007
项目编号81271606 ; 20150520154JH
资助机构National Natural Science Foundation of China (NSFC) ; Research Fund of Science and Technology Department of Jilin Province
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63000
专题北京大学医药卫生分析中心
作者单位1.Jilin Univ, Dept Nucl Med, China Japan Union Hosp, Changchun 130023, Peoples R China
2.Peking Univ, Med Isotopes Res Ctr, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Ma, Qingjie,Min, Kaiyin,Wang, Ting,et al. Tc-99m-3PRGD(2) SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab[J]. ANNALS OF NUCLEAR MEDICINE,2015,29(6):519-527.
APA Ma, Qingjie.,Min, Kaiyin.,Wang, Ting.,Chen, Bin.,Wen, Qiang.,...&Gao, Shi.(2015).Tc-99m-3PRGD(2) SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.ANNALS OF NUCLEAR MEDICINE,29(6),519-527.
MLA Ma, Qingjie,et al."Tc-99m-3PRGD(2) SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab".ANNALS OF NUCLEAR MEDICINE 29.6(2015):519-527.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ma, Qingjie]的文章
[Min, Kaiyin]的文章
[Wang, Ting]的文章
百度学术
百度学术中相似的文章
[Ma, Qingjie]的文章
[Min, Kaiyin]的文章
[Wang, Ting]的文章
必应学术
必应学术中相似的文章
[Ma, Qingjie]的文章
[Min, Kaiyin]的文章
[Wang, Ting]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。